St. Paul-based pharmaceutical company CNS Therapeutics named Andy LaFrence as its chief financial officer.
LaFrence was previously an audit partner at accounting firm KPMG.
"Andy's tremendous insight from the pharmaceutical, medical technology and financial markets is instrumental to our rapidly growing business," said CEO John Foster.
CNS Therapeutics received FDA approval last year for its generic version of a drug to treat severe spasticity.
Scott Bronson, the company's co-founder, is administrative and compliance officer. Bronson was previously CFO.
